CD19 and B-cell non-Hodgkin lymphoma: Clinical trials performed on patients with aggressive B-cell lymphoma have indicated that using CD19/CD22 dual-targeted CAR-Ts not only enhanced the cytotoxic effect against leukemia cells but also reduced the risk of relapse due to the loss of CD19 expression, which is a common resistance mechanism in CAR-T therapy [65].